Leerink Partners Upgrades Gossamer Bio Stock Rating Amid Institutional Buying
2 reports, 2 independent
Updated Oct 13
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners upgraded Gossamer Bio stock rating on September 26, 2026. Separately, institutional investors have shown significant buying interest in Gossamer Bio, with Hsbc Holdings PLC increasing its holdings by 1,289.4% during the second quarter.
From tickerreport.com
Why it matters
The analyst upgrade, alongside substantial institutional accumulation, suggests increased investor confidence in Gossamer Bio. This positive market signal could intensify competitive pressure on Candel Therapeutics.
From tickerreport.com
Who's involved
- Leerink partnersU.S. investment bank that upgraded the stock rating
How it developed
Newest first. Tap a step to see who reported it.Rockefeller Capital Management raised its stake by 496.7% and Gossamer Bio received an outperform rating.1 source
Leerink Partners upgraded Gossamer Bio stock rating.1 source
Keep exploring
The entities involved
-
Leerink partners
U.S. investment bank